Evidence map›Paper›PMID 41684598›Full record

ArticleFrontiers in oncology2026

A radiotherapeutic paradox: ellagic acid sensitizes tumors while attenuating radiation-induced myocardial injury.

Dandan Li, Siqin Xie, Sisi Yang, Chenghao Zhu, Haomiao Lan, Ke Zhu, Ziyang Zhu, Kun Wang, Fuqiang Shao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dandan Li *Department of Nuclear Medicine, The First People's Hospital of Zigong, Zigong, Sichuan, China.
Siqin Xie *Department of Ultrasonography, Wuhan Children's Hospital (Wuhan Maternal and Child Health Care Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Sisi Yang *Department of Thyroid & Breast Surgery, Zigong First People's Hospital, Zigong Academy of Medical Sciences, Zigong, China.
Chenghao ZhuMedical Department, Wuhan City College, Wuhan, China.
Haomiao LanDepartment of Thyroid & Breast Surgery, Zigong First People's Hospital, Zigong Academy of Medical Sciences, Zigong, China.
Ke ZhuDepartment of Nuclear Medicine, The First People's Hospital of Zigong, Zigong, Sichuan, China.
Ziyang ZhuDepartment of Nuclear Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Kun WangDepartment of Nuclear Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Fuqiang ShaoDepartment of Nuclear Medicine, The First People's Hospital of Zigong, Zigong, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer lacking effective targeted therapies. Radiotherapy remains a mainstay for locoregional control, but its efficacy is limited by intrinsic tumor radioresistance and the risk of radiation-induced myocardial injury (RIMI), particularly during chest irradiation. This study aimed to investigate whether ellagic acid, a naturally occurring polyphenol, could simultaneously enhance radiosensitivity in TNBC while protecting cardiac tissue from radiation-induced damage. Methods: We employed both Results: Ellagic acid effectively induced G1-phase cell cycle arrest and suppressed CDK4, thereby reducing S-phase entry and enhancing radiation-induced apoptosis in TNBC cells. Conclusion: Ellagic acid exhibits a unique dual function in TNBC radiotherapy: it sensitizes tumors by targeting the CARM1-CDK4 axis while protecting the heart through potent antioxidant activity. These findings position ellagic acid as a promising adjuvant candidate to enhance therapeutic efficacy and safety in TNBC radiotherapy.

Indexed as

ellagic acidradiation-induced myocardial injuryradiosensitizingradiotherapytriple-negative breast cancer

Identifiers

PMID41684598
PMCPMC12890680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.